Market cap
$2,624 Mln
Revenue (TTM)
$379 Mln
P/E Ratio
--
P/B Ratio
70
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | -4.38 | 84.11 | 91.46 | 432.40 | -- |
| EBIT | -53.87 | 15.70 | 32.25 | 14.27 | -5.50 |
| Net Profit | -26.32 | 9.17 | 19.42 | 11.48 | -15.73 |
| EPS | -25.02 | 12.92 | 22.51 | 14.16 | 1.06 |
| Book Value | -- | -- | -- | -- | -- |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | TTM | Mar-22 | Mar-21 |
| EBIT-Margin
| -246.48 | -10,162.58 | -37.90 | -80.95 | -412.02 |
| Net Margin
| 14,065.90 | 14,065.90 | -48.06 | -89.03 | -337.02 |
| Return on equity
| 238.74 | -144.91 | -- | 49.79 | 110.39 |
| Return on Capital
| -510.78 | -388.68 | -- | 458.46 | -1,515.68 |
| Return on Assets
| -100.58 | -116.63 | -24.14 | -33.09 | -61.41 |
| Debt to Equity (x)
| -- | -- | -0.64 | -0.78 | -1.04 |
Profitability
ROCE
--
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
TTM
|
Mar-22
|
Mar-21
|
Mar-20
|
Mar-19
|
|---|---|---|---|---|---|
|
Myovant Sciences (MYOV)
|
--
|
458.46
|
-1,515.68
|
-475.11
|
-295.62
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROE
--
--
Profit after tax / Average Net worth * 100
|
Company Name
|
TTM
|
Mar-22
|
Mar-21
|
Mar-20
|
Mar-19
|
|---|---|---|---|---|---|
|
Myovant Sciences (MYOV)
|
--
|
49.79
|
110.39
|
556.05
|
-1,300.67
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROA
-24.14
--
Profit after tax / Average Total assets * 100
|
Company Name
|
TTM
|
Mar-22
|
Mar-21
|
Mar-20
|
Mar-19
|
|---|---|---|---|---|---|
|
Myovant Sciences (MYOV)
|
-24.14
|
-33.09
|
-61.41
|
-207.23
|
-187.31
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EBIT Margin
-37.90
--
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
TTM
|
Mar-22
|
Mar-21
|
Mar-20
|
Mar-19
|
|---|---|---|---|---|---|
|
Myovant Sciences (MYOV)
|
-37.90
|
-80.95
|
-412.02
|
--
|
-29,994.78
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Net Margin
-48.06
--
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
TTM
|
Mar-22
|
Mar-21
|
Mar-20
|
Mar-19
|
|---|---|---|---|---|---|
|
Myovant Sciences (MYOV)
|
-48.06
|
-89.03
|
-337.02
|
42,623.75
|
-31,050.06
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Cash Profit Margin
0.00
--
(Net profit + Depreciation) / Gross Sales * 100
|
Company Name
|
TTM
|
Mar-22
|
Mar-21
|
Mar-20
|
Mar-19
|
|---|---|---|---|---|---|
|
Myovant Sciences (MYOV)
|
0.00
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Revenue Growth
91.46
--
Year on year growth in net sales
|
Company Name
|
TTM
|
Mar-22
|
Mar-21
|
Mar-20
|
Mar-19
|
|---|---|---|---|---|---|
|
Myovant Sciences (MYOV)
|
91.46
|
2.89
|
--
|
-1.00
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EBIT Growth
32.25
--
Year on year growth in operating profit (EBIT)
|
Company Name
|
TTM
|
Mar-22
|
Mar-21
|
Mar-20
|
Mar-19
|
|---|---|---|---|---|---|
|
Myovant Sciences (MYOV)
|
32.25
|
23.50
|
11.31
|
-4.28
|
-87.42
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Net Profit Growth
19.42
--
Year on year growth in profit after tax
|
Company Name
|
TTM
|
Mar-22
|
Mar-21
|
Mar-20
|
Mar-19
|
|---|---|---|---|---|---|
|
Myovant Sciences (MYOV)
|
19.42
|
19.27
|
11.71
|
-5.64
|
-90.95
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EPS Growth
22.51
--
Year on year growth in earnings per share
|
Company Name
|
TTM
|
Mar-22
|
Mar-21
|
Mar-20
|
Mar-19
|
|---|---|---|---|---|---|
|
Myovant Sciences (MYOV)
|
22.51
|
0.22
|
0.16
|
0.18
|
-0.71
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Book Value Growth
-23.79
--
Year on year growth in book value per share
|
Company Name
|
TTM
|
Mar-22
|
Mar-21
|
Mar-20
|
Mar-19
|
|---|---|---|---|---|---|
|
Myovant Sciences (MYOV)
|
-23.79
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
-0.64
--
Total debt / Net worth
|
Company Name
|
TTM
|
Mar-22
|
Mar-21
|
Mar-20
|
Mar-19
|
|---|---|---|---|---|---|
|
Myovant Sciences (MYOV)
|
-0.64
|
-0.78
|
-1.04
|
-1.17
|
22.93
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Short term debt to equity ratio
0.00
--
(Short term borrowings / Net worth)
|
Company Name
|
TTM
|
Mar-22
|
Mar-21
|
Mar-20
|
Mar-19
|
|---|---|---|---|---|---|
|
Myovant Sciences (MYOV)
|
0.00
|
0.00
|
-0.01
|
-0.01
|
1.42
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
1.57
--
Current Assets / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Mar-22
|
Mar-21
|
Mar-20
|
Mar-19
|
|---|---|---|---|---|---|
|
Myovant Sciences (MYOV)
|
1.57
|
1.95
|
2.50
|
1.02
|
2.32
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Quick Ratio
1.45
--
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Mar-22
|
Mar-21
|
Mar-20
|
Mar-19
|
|---|---|---|---|---|---|
|
Myovant Sciences (MYOV)
|
1.45
|
1.92
|
2.50
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Interest Coverage
-7.71
--
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
TTM
|
Mar-22
|
Mar-21
|
Mar-20
|
Mar-19
|
|---|---|---|---|---|---|
|
Myovant Sciences (MYOV)
|
-7.71
|
-13.38
|
-23.50
|
-21.76
|
-29.96
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Operating Efficiency
Debtors to sales
11.61
--
Debtors outstanding / Net Sales * 100
|
Company Name
|
TTM
|
Mar-22
|
Mar-21
|
Mar-20
|
Mar-19
|
|---|---|---|---|---|---|
|
Myovant Sciences (MYOV)
|
11.61
|
10.34
|
6.02
|
--
|
59.48
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Asset Turnover
0.50
--
Sales / Average Total Assets
|
Company Name
|
TTM
|
Mar-22
|
Mar-21
|
Mar-20
|
Mar-19
|
|---|---|---|---|---|---|
|
Myovant Sciences (MYOV)
|
0.50
|
0.37
|
0.14
|
--
|
0.01
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Receivable days
--
--
Average Debtors / Sales * 365
|
Company Name
|
TTM
|
Mar-22
|
Mar-21
|
Mar-20
|
Mar-19
|
|---|---|---|---|---|---|
|
Myovant Sciences (MYOV)
|
--
|
21.70
|
21.98
|
--
|
315.91
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Inventory Days
--
--
Average Inventory / Sales * 365
|
Company Name
|
TTM
|
Mar-22
|
Mar-21
|
Mar-20
|
Mar-19
|
|---|---|---|---|---|---|
|
Myovant Sciences (MYOV)
|
--
|
36.12
|
485.33
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
--
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
TTM
|
Mar-22
|
Mar-21
|
Mar-20
|
Mar-19
|
|---|---|---|---|---|---|
|
Myovant Sciences (MYOV)
|
--
|
106.49
|
3,080.28
|
--
|
322.91
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Cash Conversion Cycle
--
--
Receivable Days + Inventory Days - Payable Days
|
Company Name
|
TTM
|
Mar-22
|
Mar-21
|
Mar-20
|
Mar-19
|
|---|---|---|---|---|---|
|
Myovant Sciences (MYOV)
|
--
|
-48.67
|
-2,572.97
|
--
|
-7.00
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
--
--
Current share price divided by earning per share in the last twelve months
|
Company Name
|
TTM
|
Mar-22
|
Mar-21
|
Mar-20
|
Mar-19
|
|---|---|---|---|---|---|
|
Myovant Sciences (MYOV)
|
--
|
-6.01
|
-7.26
|
-2.25
|
-5.85
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Price / Book Value
70.01
--
Current share price divided by book value per share in the latest financial year
|
Company Name
|
TTM
|
Mar-22
|
Mar-21
|
Mar-20
|
Mar-19
|
|---|---|---|---|---|---|
|
Myovant Sciences (MYOV)
|
70.01
|
-2.62
|
-5.23
|
-6.00
|
369.01
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Dividend Yield
--
--
Dividend per share in the past twelve months divided by current share price
|
Company Name
|
TTM
|
Mar-22
|
Mar-21
|
Mar-20
|
Mar-19
|
|---|---|---|---|---|---|
|
Myovant Sciences (MYOV)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EV/EBITDA
-17.34
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
TTM
|
Mar-22
|
Mar-21
|
Mar-20
|
Mar-19
|
|---|---|---|---|---|---|
|
Myovant Sciences (MYOV)
|
-17.34
|
-6.38
|
-6.35
|
-2.54
|
-5.85
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Market Cap
2,624
--
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
TTM
|
Mar-22
|
Mar-21
|
Mar-20
|
Mar-19
|
|---|---|---|---|---|---|
|
Myovant Sciences (MYOV)
|
2,624
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|